KRAS and neoplasm: AMG 510 (Sotorasib), approved by the FDA in 2021, is the first small molecular inhibitor targeting specific KRAS gene mutations.50 It leverages the unique chemical properties of the cysteine (Cys) residue in the KRAS G12C mutant to covalently bind to this residue, locking KRAS G12C in an inactive state and preventing it from binding to GTP, thereby inhibiting KRAS-mediated downstream signaling pathways and suppressing tumor growth.51 The launch of AMG 510 signifies a milestone in the “undruggable” proteins’ history.